Key result
Dual GLP-1 RA plus SGLT2i is linked to longer six-month survival vs monotherapy, averaging ~5.9 months.
Cohort (n=134)
Yes
Answers are grounded in this paper and cite their sources.
Dual therapy was associated with modestly higher short-term survival in HFpEF; hypothesis-generating and requires randomized confirmation before practice change.
Background GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant cardiometabolic benefits in patients with type 2 diabetes mellitus, obesity, and heart failure with preserved ejection fraction (HFpEF). However, their combined impact in patients with obstructive sleep apnea (OSA), a condition associated with increased cardiovascular risk, remains insufficiently explored. Methods This prospective cohort study was conducted across three outpatient centers between Jan 2022 and June 2024. A total of 134 patients meeting eligibility criteria were stratified into three groups: GLP-1 RA + SGLT2i (n=54), GLP-1 RA therapy (n=31), and SGLT2i therapy (n=49). As a condition for inclusion, all patients had therapy initiated with GLP-1 RA or SGLT2i within two weeks of enrollment. HFpEF was confirmed through echocardiography and NT-proBNP levels >125 pg/mL, while OSA severity was assessed using ApneaLink. Patients were followed for six months. Exclusion criteria included recent CPAP initiation, NYHA class IV, advanced renal disease and severe pulmonary conditions. Results BMI significantly decreased in the combination group (38.02 ± 5.44 to 34.96 ± 4.91 kg/m², p < 0.001) and in the GLP-1 RA group (p = 0.004), whereas the reduction in the SGLT2i group was not statistically significant (p = 0.078). AHI improved in the combination and GLP-1 RA groups (both p < 0.001), while no significant change was observed in the SGLT2i group (p = 0.112).NT-proBNP significantly declined with combination therapy (966.28 ± 451.60 to 756.19 ± 436.91 pg/mL, p < 0.001) and GLP-1 RA (p = 0.005), whereas the reduction in the SGLT2i group did not reach statistical significance (p = 0.112). The E/e' ratio showed a reduction in the combination (15.40 ± 1.84 to 13.89 ± 3.54, p < 0.001) and GLP-1 RA groups (p < 0.001) compared to the SGLT2i group (p = 0.056). The TAPSE/sPAP ratio improved in the combination (0.49 ± 0.17 to 0.53 ± 0.13, p < 0.001) and GLP-1 RA groups (p < 0.001), but only modestly in the SGLT2i group (p = 0.049). KCCQ scores improved significantly in the combination (p < 0.001) and GLP-1 RA groups (p = 0.002), whereas the change in the SGLT2i group was not significant (p = 0.074).Kaplan-Meier survival analysis demonstrated a significant difference in six-month survival between groups (log-rank χ² = 6.22, p = 0.044). Mean survival was 5.9 months in the combination therapy group, 5.6 months in the GLP-1 RA group, and 5.3 months in the SGLT2i group. Conclusion In patients with HFpEF, T2DM, obesity, and OSA, dual therapy with GLP-1 RA and SGLT2i was associated with reductions in NT-proBNP levels, pulmonary pressures, and E/e' ratio, along with improvements in TAPSE/sPAP and KCCQ scores, compared to monotherapy. Combination therapy was also linked to a higher mean survival at six months. These findings suggest that dual therapy may offer superior clinical benefits in this high-risk population. Further large-scale studies are needed to validate these findings.
No takes yet. Share an insight, caveat, or question.
Voynova et al. (2025) conducted a cohort in HFpEF, T2DM, obesity, and obstructive sleep apnea (n=134). GLP-1 RA and SGLT2i dual therapy vs. GLP-1 RA or SGLT2i monotherapy was evaluated on six-month survival (p=0.044). Dual therapy with GLP-1 RA and SGLT2i was associated with higher mean survival at six months compared to GLP-1 RA and SGLT2i monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: